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Abstract
A 59-year-old kidney recipient was diagnosed with a late onset of severe chronic inﬂammatory
demyelinating polyradiculoneuropathy and almost fully recovered after stopping tacrolimus and
one course of intravenous immunoglobulin treatment. Unique features of this patient are the
unusually long time lapse between initiation of tacrolimus and the adverse effect (10 years), a
strong causality link and several arguments pointing toward an inﬂammatory etiology. When
facing new neurological signs and symptoms in graft recipients, it is important to bear in mind
the possibility of a drug-induced adverse event. Discontinuation of the suspect drug and immu-
nomodulation are useful treatment options.
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Introduction
Safety concerns about tacrolimus include neurological
adverse events (NAEs) similar to other calcineurin inhibi-
tors [1–4]. In a 1991 prospective study (n = 44), NAEs
were reported in 32% of liver transplant recipients on
tacrolimus [5]. In 2007, a large prospective study (n =
1645) reported NAEs to be present in 10–15% of patients
treated with calcineurin inhibitors for 1 year [6]. We
report here a kidney transplant recipient who developed
a life-threatening demyelinating sensorimotor polyneuro-
pathy while on tacrolimus.
Case report
A 59-year-old African-born female patient underwent
renal deceased donor heterotopic transplantation in
August 2000. Cytomegalovirus serology was negative in
the donor, positive in the recipient; Epstein-Barr virus
serology was positive in both donor and recipient. Initial
immunosuppression consisted of basiliximab 20 mg at days
0 and 4, then cyclosporine (targeted plasma level 150–200
µg/L), azathioprine (1–2 mg/kg/day) and steroids. At day 7,
cyclosporine was switched to tacrolimus (targeted plasma
level 8–10 µg/L) because of digestive intolerance. Two
episodes of mild rejection at months (M) 4 and 106 were
successfully treated.
Otherwise, creatinine and tacrolimus serum levels re-
mained stable over many years (Fig. 1).
Ten years after the graft, at M118, the patient com-
plained about painful paresthesias ﬁrst in both hands,
and 1 month later in her feet. At M120, neurological
examination revealed distal loss of touch and vibratory
sensations of four extremities. The sensory nerve action
potentials (SNAPs) were absent in the ulnar, median and
sural nerves (Tables 1 and 2). At M121, the patient was
hospitalized for stance and gait disorders. General exam-
ination was normal, tendon reﬂexes were preserved, but
all sensory modalities were reduced in her distal upper
and lower limbs. On the fourth hospital day, tacrolimus
serum level was found to be elevated at 22.2 µg/L. The
patient was found to have been erroneously receiving a
double dose since admission. This was corrected and
5 days later, the tacrolimus level had almost normalized
at 13.2 µg/L, but the neurological manifestations wor-
sened. A repeat nerve conduction study demonstrated
ﬁndings consistent with motor neuronal demyelination
and absent SNAPs (Table 1). The patient also developed
hypertension, tachycardia, profuse sweating, alternating
diarrhea–constipation, urinary incontinence, multiple
electrolyte disorders consistent with dysautonomia and
delirium related to severe hyponatremia (117 mmol/L,
normal range 135–145 mmol/L) and opiate toxicity.
Results of extensive laboratory and radiology studies
were all negative. Two days later, intravenous infusions of
immunoglobulins (IVIGs) were started (2 g/kg over
4 days), and tacrolimus was switched to sirolimus. With
further supportive treatment, all symptoms improved
rapidly over the next 3 weeks, and the patient was
discharged home after a 2-month hospital stay (M123).
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Two months later (M125), she was independent in all
activities of daily living; however, diffuse hyporeﬂexia,
bilateral hypoesthesia in a stocking and glove distribution
with distal reduction of vibration sense, with some gait
and Romberg unsteadiness, were still present.
Discussion
Ten years after the graft, this 59-year-old kidney trans-
plant recipient experienced a life-threatening sensorimo-
tor peripheral neuropathy strongly suggesting a diagnosis
of chronic inﬂammatory demyelinating polyradiculo-
neuropathy (CIDP). A tacrolimus-induced adverse event
has been judged probable (score of 5/13 according to the
Naranjo Adverse Drug Reaction Probability Scale) [7].
We identiﬁed 12 other published reports of tacrolimus-
related polyneuropathy [8–15]. The onset was within
the ﬁrst 3 months after initiation of tacrolimus in most
of the patients, but one presented with symptoms after
10 months of treatment. Tacrolimus blood levels were
described as over the target range in ﬁve cases. Demyeli-
nating type of neuropathy was predominant. In contrast,
tacrolimus has been used as an immunosuppressant
treatment in two cases of primary CIDP [16, 17].
The underlying mechanism in our patient is probably
inﬂammatory and non-toxic, given the fast and excellent
response to the single course of IVIGs. The cause of
inﬂammation is undetermined and some undiagnosed
infection remains a possibility. Autoimmune damage is
another possibility, a tacrolimus-triggered event in the
context of dysimmunity in this graft recipient being
possible.
In summary, our case contributes quite unique fea-
tures of what is already known on tacrolimus-induced
neuropathy:
1. The adverse effect occurred 10 years after initiation
of tacrolimus.
2. A causal role of tacrolimus is suggested by a sugges-
tive temporal relationship, long-term response after ces-
sation of treatment, exclusion of other causes, some
degree of dose–response relationship during transient
overdosage and consistency with previously published
cases.
3. Tacrolimus could be switched safely to sirolimus. Sir-
olimus-induced neurotoxicity has rarely been described
[18, 19]. In our patient, it has been well tolerated so far
after an ongoing treatment of 18 months.
In conclusion, this case illustrates that a drug-induced
adverse reaction may occur a long time after starting ta-
crolimus. Early discontinuation of the offending drug and
immunomodulation by IVIGs are the key components of
management given the potential for a life-threatening
course.
Conﬂict of interest statement. None declared.
Fig. 1. Tacrolimus whole blood levels (cross symbols) and clinical ﬁndings
over time following transplantation. 0 = graft; M =month post-graft; D = days
after 1st neurological manifestations; IVIGs=intravenous immunoglobulins.
Overall disability sum score (ﬁlled circles) was retrospectively calculated
according to Merkies ISJ et al., J Neurol Neurosurg Psychiatry, 2002.
Tacrolimus whole blood levels were quantiﬁed by means of an
immunoassay. (A) Variations of tacrolimus levels from M17 to M117 (full line
=mean level, dotted lines = highest and lowest levels ever measured).
(B) Onset of neurological manifestations at M118 = D0. (C) First neurological
impairment at D94. (D) Switch from tacrolimus to sirolimus and beginning of
IVIGs at D105. (E) First clinical improvement at D106.
Table 1. Results of nerve conduction studies (right side unless otherwise mentioned) at months 2.5 (A), 4 (B) and 7 (C) after the onset of neurological
manifestationsa
Nerve Recording site Parameters A B C Normal
Motor studies
Median Abductor pollicis brevis Distal latency (ms) 4.5 17.4 <4.0
Amplitude (mV) 6.8 0.2 >5
Duration (ms) 10 37.8 <6
CV (m/s) 52 0 >50
Tibial Abductor hallucis Distal latency (ms) NR 0 <6.5
Amplitude (mV) >3
Peroneal Extensor digitorum brevis (Tibialis anterior) Distal latency (ms) 7.5 0(6) 12 <6.0 (<2.0)
Amplitude (mV) 0.4 (0.1) 0.4 >3 (>4)
Duration (ms) (15) 15 <6 (<8)
F-wave latency (ms) 0 <52
Sensory studies
Median (digit 2) Wrist Amplitude (μV) 0 NR >7
Sural Ankle (right and left) Amplitude (μV) 0 0 0 >5
aData are all abnormal, characterized by prolonged distal motor latencies and desynchronization of the motor responses, and absence of sensory
responses, suggestive of sensorimotor demyelinating neuropathy—ms, milliseconds; μV or mV, micro or millivolts; m/s, metre/second; CV, conduction
velocity; NR, not recorded; 0, absent.
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Table 2. Main characteristics of the 12 reported cases of tacrolimus-induced neuropathy (references in text)a
References
Sex, age in
years
Type of
graft
Tacrolimus treatment
details
Symptoms onset
(time after
transplant) Clinical signs
Type of conduction
abnormalities Treatment Outcome
Ayres et al.
[8]
Male, 31 Liver tacrolimus 0.3 mg/kg
daily from day 7 after
transplant
D8 Flaccid quadriparesis;
Renal failure
Motor axonal Complete resolution
within a few days
Complete recovery
Ayres et al.
[8]
Male, 58 Liver po from D7 on,
0.3 mg/kg/d
D8 Flaccid quadriparesis Motor, axonal Tacrolimus
withdrawal
Complete recovery
Wilson et al.
[15]
Male, 57
(diabetes
mellitus)
Liver None given Shortly after Paresthesias, and foot
drops over 6 months
Multifocal, demyelinating PLEX over 10 days Improvement over
months
Wilson et al.
[15]
Male, 60 Liver None given D14 Distal paresthesias,
walking difﬁculties over 2
months
Multifocal, demyelinating PLEX over 10 days,
and IVIGs
Improvement over
months
Wilson et al.
[15]
Male, 35
(alcoholic
cirrhosis)
Liver None given D14 Distal paresthesias with
weakness, bedridden
Sensori-motor, axonal IVIGs over 3 days Improvement over
3 weeks, then lost to
follow-up
Bronster
et al. [11]
Male, 45 Liver Complex (see
reference)
Over the 4 months
following transplant
Disabling distal
paresthesias
Generalized,
demyelinating
Tacrolimus switched
to cyclosporine
Improvement over weeks
Laham et al.
[14]
Male, 40 Kidney Complex (see
reference)
D14 Distal muscle weakness Multifocal, demyelinating Withdrawal of
tacrolimus; IVIGs
over 5 days
Recovery within 19 weeks
Boukriche
et al. [10]
Male, 52 Lung Tacrolimus plasma level
elevated
D3 Distal paresthesias,
weakness and inability
to walk
Sensori-motor, axonal Transient cessation
of tacrolimus
Improvement over
months
Bhagavati
et al. [9]
Female, 44 Kidney 3 mg bid 10 months Facial twitching and
numbness, gait
dysbalance
Demyelinating, involving
limbs and cranial nerves
IVIGs over 5 days Improvement over
months, recovery after 3
months
Bhagavati
et al. [9]
Male, 53 Kidney 12 mg, then 7 mg bid Immediately None given Diffuse, predominantly
axonal neuropathy
Tacrolimus dose
reduced to 2 mg bid
Resolution after 5–6
weeks
De Weerdt
et al. [12]
Female, 44 Liver and
pancreas
Tacrolimus 0.04-0.08
mg/kg
D9 Distal muscle weakness Asymmetric motor
axonal
Tacrolimus dose
reduced, IVIGs over
5 days
Improvement over
months (walking aids
after 2 years)
Labate et al.
[13]
Female, 56 Heart Tacrolimus 5 mg bid 2 months Progressive paresthesias
in the lower limbs
Symmetric, sensorimotor
demyelinating
Tacrolimus switched
to cyclosporine
Improvement over
months
aD, days post-graft; iv, intravenous; IVIGs, intravenous immunoglobulins.
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